| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA930: Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments |
|
Medicine details |
|
| Medicine name | lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) |
| Formulation | 1,000 MBq/ml solution for injection/infusion |
| Reference number | 4682 |
| Indication | Treatment of adult male patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy (ARDT) and a taxane-base chemotherapy or who are not medically suitable for taxanes |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 19/10/2022 |
| NICE guidance | |